Dynavax to Present at 2025 Wells Fargo Healthcare Conference
ByAinvest
Wednesday, Aug 27, 2025 4:07 pm ET1min read
DVAX--
The company's participation in the conference follows recent positive topline results from Part 1 of its Phase 1/2 clinical trial of Z-1018, an investigational shingles vaccine candidate [2]. The trial demonstrated robust immune responses and a favorable tolerability profile, with Z-1018 achieving a 100% humoral vaccine response rate compared to the currently licensed shingles vaccine, Shingrix. Dynavax has selected the 100 mcg dose of gE antigen, adjuvanted with CpG 1018 and alum, and using an 8-week dosing interval, to advance into Part 2 of the Phase 1/2 trial in adults 70 years of age and older [2].
Dynavax's participation in the Wells Fargo Healthcare Conference provides an opportunity for investors and financial professionals to gain insights into the company's latest developments and future prospects. The company's Chief Executive Officer, Ryan Spencer, and Chief Medical Officer, Robert Janssen, will likely discuss the potential of Z-1018 to disrupt the multi-billion-dollar shingles vaccine market and the company's broader vaccine pipeline [2].
References:
[1] https://www.stocktitan.net/news/DVAX/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-sh60gajk3qr5.html
[2] https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting
Dynavax Technologies Corporation will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd. The Company's presentations will be webcast on its website. Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect against infectious diseases. Its marketed products include HEPLISAV-B vaccine and CpG 1018 adjuvant.
Dynavax Technologies Corporation (Nasdaq: DVAX) will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd. The event will be webcast on the company's website. Dynavax is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to protect against infectious diseases. Its current marketed products include HEPLISAV-B vaccine and CpG 1018 adjuvant.The company's participation in the conference follows recent positive topline results from Part 1 of its Phase 1/2 clinical trial of Z-1018, an investigational shingles vaccine candidate [2]. The trial demonstrated robust immune responses and a favorable tolerability profile, with Z-1018 achieving a 100% humoral vaccine response rate compared to the currently licensed shingles vaccine, Shingrix. Dynavax has selected the 100 mcg dose of gE antigen, adjuvanted with CpG 1018 and alum, and using an 8-week dosing interval, to advance into Part 2 of the Phase 1/2 trial in adults 70 years of age and older [2].
Dynavax's participation in the Wells Fargo Healthcare Conference provides an opportunity for investors and financial professionals to gain insights into the company's latest developments and future prospects. The company's Chief Executive Officer, Ryan Spencer, and Chief Medical Officer, Robert Janssen, will likely discuss the potential of Z-1018 to disrupt the multi-billion-dollar shingles vaccine market and the company's broader vaccine pipeline [2].
References:
[1] https://www.stocktitan.net/news/DVAX/dynavax-to-participate-in-the-2025-wells-fargo-healthcare-sh60gajk3qr5.html
[2] https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-positive-topline-phase-12-results-supporting
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet